SLC5A2 and hydrops fetalis: After a mean follow-up period of 3 years, patients administered SGLT-2 inhibitors at discharge experienced a significant reduction in the risk for all-cause death by 68%, whereas no significant effect on the risk for cardiovascular death, AMI, stroke, or hospitalization for HF was shown [44].